Minimus Spine

Minimus Spine has developed a product to treat herniated spinal discs without surgery. The product is called Triojection and it facilitates a safe, consistent injection of ozone gas into a herniated disc. There is growing evidence in the international literature in support of ozone as a treatment for disc herniation and it has the potential for broader application.

While the literature provides direct evidence comparing ozone injection to epidural steroid injections. Minimus believes that Triojection may help a percentage of patients avoid discectomy and is now supporting a multi-center, randomized clinical study in Europe to directly compare Triojection to surgical discectomy.

Triojection was CE Marked in 2014 and is soon to be commercially available in Europe. It is not currently available in the United States.

Follow-us on twitter (MinimusSpine).

Company’s Keywords:

biotechnology, medical devices, europe, bio-pharm, life sciences, medical, health care, interventional radiology, spine surgery, pain management